Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer

Patients exhibiting pancreatic cancer possess poor rates of survival. Therefore, the identification of a biomarker that can be measured non-invasively and be used to predict patient outcomes is required for the successful treatment of pancreatic cancer. The present study evaluated serum microRNA (mi...

Descripción completa

Detalles Bibliográficos
Autores principales: TIAN, XUEFEI, SHIVAPURKAR, NARAYAN, WU, ZHENG, HWANG, JIMMY J., PISHVAIAN, MICHAEL J., WEINER, LOUIS M., LEY, LISA, ZHOU, DAN, ZHI, XIULING, WELLSTEIN, ANTON, MARSHALL, JOHN L., HE, AIWU RUTH
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774452/
https://www.ncbi.nlm.nih.gov/pubmed/26998056
http://dx.doi.org/10.3892/ol.2016.4101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774452/
https://www.ncbi.nlm.nih.gov/pubmed/26998056
http://dx.doi.org/10.3892/ol.2016.4101

Ejemplares similares